STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13G: Lynch Reports 4.09M Shares of Evolus (EOLS)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Timothy P. Lynch reported beneficial ownership of 4,094,489 shares of Evolus, Inc. common stock, representing 6.3% of the class based on 64,685,419 shares outstanding as of August 1, 2025. The filing shows Mr. Lynch holds 3,492,130 shares with sole voting and dispositive power and 602,359 shares with shared voting and dispositive power. The Schedule identifies the issuer's principal executive offices at 520 Newport Center Drive, Newport Beach, California.

The filing is a Schedule 13G and includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. The reporting person’s address is listed as 70 SW Century Dr, STE 100 PMB 1257, Bend, OR 97702, and the signature is dated 08/15/2025.

Positive

  • Material ownership disclosed: Reporting person holds 4,094,489 shares, representing 6.3% of outstanding common stock.
  • Clear power breakdown: 3,492,130 shares with sole voting and dispositive power and 602,359 shares with shared power.
  • Filed as Schedule 13G with certification: The filing explicitly states the securities are not held to influence control of the issuer.

Negative

  • None.

Insights

Disclosure shows a passive 6.3% stake by an individual investor, filed on Schedule 13G.

The filing discloses a non-controlling position: 4,094,489 shares (6.3% of 64,685,419 shares outstanding) with 3,492,130 shares held with sole voting/dispositive power and 602,359 shares held with shared power. The use of Schedule 13G and the signature certification indicate the reporting person represents the holdings are not intended to influence control of the issuer. For investors, this is a material ownership disclosure but not an active control filing.

Material ownership disclosed but explicitly characterized as passive under Schedule 13G.

The report meets disclosure norms by identifying issuer, CUSIP, reporting person, address, and precise breakdown of voting and dispositive powers. The certification attached affirms the position is not held to change control, which is consistent with a Schedule 13G filing rather than a Schedule 13D. The disclosure provides transparency on an investor exceeding the 5% threshold while asserting passive intent.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based on 64,685,419 shares of Common Stock outstanding as of August 1, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G



Timothy P. Lynch
Signature:/s/ Timothy P. Lynch
Name/Title:Reporting person
Date:08/15/2025

FAQ

What stake in Evolus (EOLS) did Timothy P. Lynch disclose?

He disclosed beneficial ownership of 4,094,489 shares, equal to 6.3% of the company's common stock based on 64,685,419 shares outstanding.

Does the filing indicate Mr. Lynch seeks to influence control of Evolus?

No. The Schedule 13G includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

How many shares does Mr. Lynch have sole voting power over?

He has sole voting (and sole dispositive) power over 3,492,130 shares.

When was the Schedule 13G signed and by whom?

The filing is signed by /s/ Timothy P. Lynch as reporting person, dated 08/15/2025.

What address is listed for the issuer in the filing?

The issuer's principal executive offices are listed as 520 Newport Center Drive Suite 1200, Newport Beach, California 92660.
Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

447.90M
53.53M
11.81%
91.06%
17.98%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH